Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07416123 · ClinicalTrials.gov registry record · Phase 1
A Study of GEN1106 in Participants With Solid Tumors
A Phase 1 study of Solid Tumors and Urothelial Carcinoma, sponsored by Genmab.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 103
- Enrollment target
- 3
- Study locations
NCT07416123: Recruiting Phase 1 study of Solid Tumors and Urothelial Carcinoma, sponsored by Genmab.
NCT07416123 is a Phase 1 study of Solid Tumors and Urothelial Carcinoma that is actively recruiting participants, run by Genmab. The registered enrollment target is 103 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (64% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07416123, a Phase 1 study of Solid Tumors and Urothelial Carcinoma, is actively recruiting participants, sponsored by Genmab.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 103 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this trial is to learn about the safety and effectiveness of GEN1106 when it is used for the treatment of participants with certain types of cancer. The trial has multiple parts. The first part of the trial tests different doses of GEN1106 to find out if it is safe and determine what are the best doses to use. The second and third parts continues to test the safety of and how well GEN1106 works in additional participants with a specific cancer type and at doses chosen based on results from the first part of the trial. For each participant, the trial will last approximately 17 months but will vary for each person. This includes up to 21 days for screening prior to receiving trial treatment, approximately 5 months of treatment (the duration of treatment may vary for each participant), and approximately 11 months of follow up after trial treatment ends (the duration of follow up may vary for each participant). Participation in the trial will require visits to the site, with more frequent visits during the first 6 weeks of treatment and then less frequent visits afterwards. At site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, computed tomography \[CT\] scans) to monitor whether the treatment is safe and effective. All participants will receive active drug; no one will be given placebo.
Conditions Studied
Interventions
- BIOLOGICAL GEN1106
Study Locations (3)
New York
- START New York Long Island LLC - Lake Success
South Carolina
- Carolina Urologic Research Center - Myrtle Beach
Texas
- South Texas Accelerated Research Therapeutics - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2026-03 |
| Est. Completion | 2029-06-25 |
| Phase | Phase 1 |
What NCT07416123 shows while recruiting
NCT07416123 is an interventional study that assigns participants to a tested intervention. The registered 103 participants enrollment target is mid-sized for trials with a published cap, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (64% lower).
The record links to 2 conditions, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which GEN1106 is the first listed.
NCT07416123 reports a single indexed study location in New York, South Carolina, Texas.
Frequently Asked Questions
What is clinical trial NCT07416123 about?
NCT07416123 is a clinical study titled "A Study of GEN1106 in Participants With Solid Tumors". The purpose of this trial is to learn about the safety and effectiveness of GEN1106 when it is used for the treatment of participants with certain types of cancer. The trial has multiple parts. The first part of the trial tests different doses of GEN1106 to find out if it is safe and determine what...
What is the current status of trial NCT07416123?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 103 participants. The study started on 2026-03. Estimated completion is 2029-06-25.
What conditions does trial NCT07416123 study?
This clinical trial studies the following conditions: Solid Tumors, Urothelial Carcinoma.
What interventions are being tested in trial NCT07416123?
The interventions under investigation include: GEN1106 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07416123?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07416123 being conducted?
This trial has 3 study locations across New York, South Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07416123's enrollment target sits among peer trials
103 51st of 125 higher than 74 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04690348 · 103 participants · Phase 2
Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study
- NCT05282277 · 103 participants · Phase 4
Examining the Effects of Estradiol on Neural and Molecular Response to Reward
- NCT05566769 · 103 participants · NA
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
- NCT05834478 · 103 participants · Phase 3
Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia